Cancer Causes & Control

, Volume 23, Issue 7, pp 1099–1111 | Cite as

Statin use and risk of pancreatic cancer: a meta-analysis

  • Xiaobing Cui
  • Yue Xie
  • Min Chen
  • Jun Li
  • Xiaoming Liao
  • Jian Shen
  • Meng Shi
  • Wenjing Li
  • Haoxuan Zheng
  • Bo Jiang
Original paper

Abstract

Purpose

Statins are commonly prescribed medications that potently reduce cholesterol levels and the risk of cardiovascular events. Preclinical studies suggested statins also possess cancer chemopreventive properties. However, the clinical studies provided contradictory results as to whether statins influence the risk of pancreatic cancer. Herein, we present this meta-analysis to assess the association between statin use and risk of pancreatic cancer.

Methods

We conducted a comprehensive search up to August 2011 for the eligible studies. Pooled relative risk (RR) estimates and corresponding 95 % confidence intervals (CIs) were calculated using the inverse-variance-weighted random-effects model. Subgroup analyses were conducted where data were available. Heterogeneity was assessed by the Cochran’s Q test and the I2 statistic.

Results

We included 16 studies that involving 1,692,863 participants and 7,807 pancreatic cancer cases. Pooled results only indicated a non-significant decrease of pancreatic cancer risk among all statin users (RR 0.89; 95 % CIs, 0.74–1.07). Similar results were obtained in the subgroup analyses of the long-term (more than 4 years) follow-up (RR 0.94, 0.81–1.08) and statin use (RR 0.97, 0.76–1.23), and a null association was found between lipophilic statin use and pancreatic cancer risk (RR 1.03, 0.92–1.16). No evidence of publication bias was observed in the present meta-analysis. However, significant heterogeneity was detected among all studies (p < 0.00001, I2 = 81 %).

Conclusions

In conclusion, our results suggest that there is no association between statin use and pancreatic cancer risk, when statins are taken at daily doses for cardiovascular event prevention.

Keywords

Statin Pancreatic cancer Risk Prevention Meta-analysis 

Abbreviations

RR

Relative risk

CIs

Confidence intervals

RCTs

Randomized controlled trials

HMG-CoA

3-Hydroxy-3-methylglutaryl coenzyme-A

References

  1. 1.
    Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212–236. doi:10.3322/caac.20121 PubMedCrossRefGoogle Scholar
  2. 2.
    Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362(17):1605–1617. doi:10.1056/NEJMra0901557 PubMedCrossRefGoogle Scholar
  3. 3.
    Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278. doi:10.1016/S0140-6736(05)67394-1 PubMedCrossRefGoogle Scholar
  4. 4.
    Newman TB, Hulley SB (1996) Carcinogenicity of lipid-lowering drugs. JAMA 275(1):55–60PubMedCrossRefGoogle Scholar
  5. 5.
    Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9(1):10–19PubMedGoogle Scholar
  6. 6.
    Vaklavas C, Chatzizisis YS, Tsimberidou AM (2011) Common cardiovascular medications in cancer therapeutics. Pharmacol Ther 130(2):177–190. doi:10.1016/j.pharmthera.2011.01.009 PubMedCrossRefGoogle Scholar
  7. 7.
    Sumi S, Beauchamp RD, Townsend CM Jr, Uchida T, Murakami M, Rajaraman S, Ishizuka J, Thompson JC (1992) Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 103(3):982–989PubMedGoogle Scholar
  8. 8.
    Sumi S, Beauchamp RD, Townsend CM Jr, Pour PM, Ishizuka J, Thompson JC (1994) Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. Pancreas 9(5):657–661PubMedCrossRefGoogle Scholar
  9. 9.
    Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Nakamura H (2001) Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res 61(12):4885–4891PubMedGoogle Scholar
  10. 10.
    Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Inoue M, Nakamura H (2002) 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122(2):308–317PubMedCrossRefGoogle Scholar
  11. 11.
    Gbelcova H, Lenicek M, Zelenka J, Knejzlik Z, Dvorakova G, Zadinova M, Pouckova P, Kudla M, Balaz P, Ruml T, Vitek L (2008) Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer 122(6):1214–1221. doi:10.1002/ijc.23242 PubMedCrossRefGoogle Scholar
  12. 12.
    Khurana V, Sheth A, Caldito G, Barkin JS (2007) Statins reduce the risk of pancreatic cancer in humans—a case-control study of half a million veterans. Pancreas 34(2):260–265. doi:10.1097/MPA.0b013e318030e963 PubMedCrossRefGoogle Scholar
  13. 13.
    Kaye JA, Jick H (2004) Statin use and cancer risk in the general practice research database. Br J Cancer 90(3):635–637. doi:10.1038/sj.bjc.6601566 PubMedCrossRefGoogle Scholar
  14. 14.
    Bradley MC, Hughes CM, Cantwell MM, Murray LJ (2010) Statins and pancreatic cancer risk: a nested case-control study. Cancer Causes Control 21(12):2093–2100. doi:10.1007/s10552-010-9628-0 PubMedCrossRefGoogle Scholar
  15. 15.
    Chiu H-F, Chang C–C, Ho S-C, Wu T-N, Yang C-Y (2011) Statin use and the risk of pancreatic cancer a population-based case-control study. Pancreas 40(5):669–672. doi:10.1097/MPA.0b013e31821fd5cd PubMedCrossRefGoogle Scholar
  16. 16.
    Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17(1):27–36. doi:10.1002/pds.1507 PubMedCrossRefGoogle Scholar
  17. 17.
    Bonovas S, Filioussi K, Sitaras NM (2008) Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol 103(10):2646–2651. doi:10.1111/j.1572-0241.2008.02051.x PubMedCrossRefGoogle Scholar
  18. 18.
    Vitek L (2009) Statins and pancreatic cancer: are all statins the same? Am J Gastroenterol 104(2):525. doi:10.1038/ajg.2008.103 (author reply 525)PubMedCrossRefGoogle Scholar
  19. 19.
    Duncan RE, El-Sohemy A, Archer MC (2005) Statins and cancer development. Cancer Epidemiol Biomarkers Prev 14(8):1897–1898. doi:10.1158/1055-9965.EPI-05-0027 PubMedCrossRefGoogle Scholar
  20. 20.
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012PubMedCrossRefGoogle Scholar
  21. 21.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. doi:10.1136/bmj.b2535 PubMedCrossRefGoogle Scholar
  22. 22.
    Lovastatin Study Groups I Through IV (1993) Lovastatin 5-year safety and efficacy study. Arch Intern Med 153(9):1079–1087CrossRefGoogle Scholar
  23. 23.
    Olsen JH, Johansen C, Sorensen HT, McLaughlin JK, Mellemkjaer L, Steffensen FH, Fraumeni JF Jr (1999) Lipid-lowering medication and risk of cancer. J Clin Epidemiol 52(2):167–169PubMedCrossRefGoogle Scholar
  24. 24.
    Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions. http://www.cochrane-handbook.org/
  25. 25.
    Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2012) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  26. 26.
    Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59(11):1572–1585. doi:10.1136/gut.2009.190900 PubMedCrossRefGoogle Scholar
  27. 27.
    Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Pauker SG (1994) Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 14(2):108–117PubMedCrossRefGoogle Scholar
  28. 28.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560. doi:10.1136/bmj.327.7414.557 PubMedCrossRefGoogle Scholar
  29. 29.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMedCrossRefGoogle Scholar
  30. 30.
    Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101PubMedCrossRefGoogle Scholar
  31. 31.
    Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro DR, Stein EA, Langendorfer A, Beere PA, Gotto AM (2001) Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Women’s Health Gender Based Med 10(10):971–981. doi:10.1089/152460901317193549 CrossRefGoogle Scholar
  32. 32.
    Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B (2002) Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287(24):3215–3222PubMedCrossRefGoogle Scholar
  33. 33.
    Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pederson TR, Kjekshus J (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364(9436):771–777. doi:10.1016/s0140-6736(04)16936-5 PubMedCrossRefGoogle Scholar
  34. 34.
    Jacobs EJ, Newton CC, Thun MJ, Gapstur SM (2011) Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 71(5):1763–1771. doi:10.1158/0008-5472.can-10-2953 PubMedCrossRefGoogle Scholar
  35. 35.
    Marelli C, Gunnarsson C, Ross S, Haas S, Stroup DF, Cload P, Clopton P, DeMaria AN (2011) Statins and risk of cancer a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol 58(5):530–537. doi:10.1016/j.jacc.2011.04.015 PubMedCrossRefGoogle Scholar
  36. 36.
    Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J (2010) Incidence of cancer and statin usage—record linkage study. Int J Cancer 126(1):279–284. doi:10.1002/ijc.24536 PubMedCrossRefGoogle Scholar
  37. 37.
    Sato S, Ajiki W, Kobayashi T, Awata N (2006) Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol 16(5):201–206PubMedCrossRefGoogle Scholar
  38. 38.
    Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar H-J (2004) The risk of cancer in users of statins. J Clin Oncol 22(12):2388–2394. doi:10.1200/jco.2004.02.027 PubMedCrossRefGoogle Scholar
  39. 39.
    Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18(2):213–219. doi:10.1097/01.ede.0000254694.03027.a1 PubMedCrossRefGoogle Scholar
  40. 40.
    Pugh TE, Little MW, Carey FJ, Robinson RJ, Clark A, Metcalfe M, Ndokera R, Ing H, Dennison A, Hart A (2011) Aspirin, NSAIDS, calcium-channel blockers and statins in the aetiology of pancreatic cancer: preliminary results from a case-control study in two centres in the UK. Gut 60(Suppl 1):A81. doi:10.1136/gut.2011.239301.166 CrossRefGoogle Scholar
  41. 41.
    Dorais M TR, Rakel A, Lelorrier J, Panzini B (2007) Statins, nsaids and pancreatic cancer. Paper presented at the 4th Canadian therapeutics congress, Halifax, Nova Scotia, 10 May 2007. http://www.cjcp.ca/pubmed.php?articleId=113
  42. 42.
    Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84(3):413–428PubMedCrossRefGoogle Scholar
  43. 43.
    Moorman PG, Hamilton RJ (2007) Statins and cancer risk: what do we know and where do we go from here? Epidemiology 18(2):194–196. doi:10.1097/01.ede.0000254699.31405.e2 PubMedCrossRefGoogle Scholar
  44. 44.
    Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH (2007) Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 166(3):348–354. doi:10.1093/aje/kwm070 PubMedCrossRefGoogle Scholar
  45. 45.
    Boudreau DM, Yu O, Johnson J (2010) Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 9(4):603–621. doi:10.1517/14740331003662620 PubMedCrossRefGoogle Scholar
  46. 46.
    Dale KM, Coleman CI, Henyan NN, Kluger J, White CM (2006) Statins and cancer risk: a meta-analysis. JAMA 295(1):74–80. doi:10.1001/jama.295.1.74 PubMedCrossRefGoogle Scholar
  47. 47.
    Kuoppala J, Lamminpaa A, Pukkala E (2008) Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 44(15):2122–2132. doi:10.1016/j.ejca.2008.06.025 PubMedCrossRefGoogle Scholar
  48. 48.
    Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670–1681. doi:10.1016/s0140-6736(10)61350-5 PubMedCrossRefGoogle Scholar
  49. 49.
    Shimoyama S (2011) Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemother Pharmacol 67(4):729–739. doi:10.1007/s00280-011-1583-2 PubMedCrossRefGoogle Scholar
  50. 50.
    Alsheikh-Ali AA, Karas RH (2009) The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials. Curr Atheroscler Rep 11(2):100–104PubMedCrossRefGoogle Scholar
  51. 51.
    Bocci G, Fioravanti A, Orlandi P, Bernardini N, Collecchi P, Del Tacca M, Danesi R (2005) Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer 93(3):319–330. doi:10.1038/sj.bjc.6602720 PubMedCrossRefGoogle Scholar
  52. 52.
    Dimitroulakos J, Lorimer IA, Goss G (2006) Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Clin Cancer Res 12(14 Pt 2):4426s–4431s. doi:10.1158/1078-0432.CCR-06-0089 PubMedCrossRefGoogle Scholar
  53. 53.
    Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients (2012) http://clinicaltrials.gov/ct2/show/NCT00944463

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Xiaobing Cui
    • 1
  • Yue Xie
    • 1
  • Min Chen
    • 1
  • Jun Li
    • 2
  • Xiaoming Liao
    • 3
  • Jian Shen
    • 4
  • Meng Shi
    • 1
  • Wenjing Li
    • 1
  • Haoxuan Zheng
    • 1
  • Bo Jiang
    • 1
  1. 1.Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang HospitalSouthern Medical UniversityGuangzhouChina
  2. 2.Department of Joint Surgery, Nanfang HospitalSouthern Medical UniversityGuangzhouChina
  3. 3.Department of Hepatobiliary Surgery, Nanfang HospitalSouthern Medical UniversityGuangzhouChina
  4. 4.Department of Cardiology, Zhujiang HospitalSouthern Medical UniversityGuangzhouChina

Personalised recommendations